152 related articles for article (PubMed ID: 36234686)
1. Structure Activity Relationship Studies around
Brahmaiah D; Bhavani AKD; Aparna P; Kumar NS; Solhi H; Le Guevel R; Baratte B; Robert T; Ruchaud S; Bach S; Jadav SS; Reddy CR; Mosset P; Gouault N; Levoin N; Grée R
Molecules; 2022 Sep; 27(19):. PubMed ID: 36234686
[TBL] [Abstract][Full Text] [Related]
2. Discovery of DB18, a potent inhibitor of CLK kinases with a high selectivity against DYRK1A kinase.
Brahmaiah D; Kanaka Durga Bhavani A; Aparna P; Sampath Kumar N; Solhi H; Le Guevel R; Baratte B; Ruchaud S; Bach S; Singh Jadav S; Raji Reddy C; Roisnel T; Mosset P; Levoin N; Grée R
Bioorg Med Chem; 2021 Feb; 31():115962. PubMed ID: 33422908
[TBL] [Abstract][Full Text] [Related]
3. Development of Selective Clk1 and -4 Inhibitors for Cellular Depletion of Cancer-Relevant Proteins.
ElHady AK; Abdel-Halim M; Abadi AH; Engel M
J Med Chem; 2017 Jul; 60(13):5377-5391. PubMed ID: 28561591
[TBL] [Abstract][Full Text] [Related]
4. Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype.
Walter A; Chaikuad A; Helmer R; Loaëc N; Preu L; Ott I; Knapp S; Meijer L; Kunick C
PLoS One; 2018; 13(5):e0196761. PubMed ID: 29723265
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk).
Mott BT; Tanega C; Shen M; Maloney DJ; Shinn P; Leister W; Marugan JJ; Inglese J; Austin CP; Misteli T; Auld DS; Thomas CJ
Bioorg Med Chem Lett; 2009 Dec; 19(23):6700-5. PubMed ID: 19837585
[TBL] [Abstract][Full Text] [Related]
6. 10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A.
Falke H; Chaikuad A; Becker A; Loaëc N; Lozach O; Abu Jhaisha S; Becker W; Jones PG; Preu L; Baumann K; Knapp S; Meijer L; Kunick C
J Med Chem; 2015 Apr; 58(7):3131-43. PubMed ID: 25730262
[TBL] [Abstract][Full Text] [Related]
7. New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
Tazarki H; Zeinyeh W; Esvan YJ; Knapp S; Chatterjee D; Schröder M; Joerger AC; Khiari J; Josselin B; Baratte B; Bach S; Ruchaud S; Anizon F; Giraud F; Moreau P
Eur J Med Chem; 2019 Mar; 166():304-317. PubMed ID: 30731399
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, biological evaluation and molecular modeling studies of imidazo[1,2-a]pyridines derivatives as protein kinase inhibitors.
Lawson M; Rodrigo J; Baratte B; Robert T; Delehouzé C; Lozach O; Ruchaud S; Bach S; Brion JD; Alami M; Hamze A
Eur J Med Chem; 2016 Nov; 123():105-114. PubMed ID: 27474927
[TBL] [Abstract][Full Text] [Related]
9. Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases.
Lindberg MF; Deau E; Arfwedson J; George N; George P; Alfonso P; Corrionero A; Meijer L
J Med Chem; 2023 Mar; 66(6):4106-4130. PubMed ID: 36876904
[TBL] [Abstract][Full Text] [Related]
10. Development of novel 2,4-bispyridyl thiophene-based compounds as highly potent and selective Dyrk1A inhibitors. Part I: Benzamide and benzylamide derivatives.
Darwish SS; Abdel-Halim M; Salah M; Abadi AH; Becker W; Engel M
Eur J Med Chem; 2018 Sep; 157():1031-1050. PubMed ID: 30193214
[TBL] [Abstract][Full Text] [Related]
11. Novel CLK1 inhibitors based on N-aryloxazol-2-amine skeleton - A possible way to dual VEGFR2 TK/CLK ligands.
Murár M; Dobiaš J; Šramel P; Addová G; Hanquet G; Boháč A
Eur J Med Chem; 2017 Jan; 126():754-761. PubMed ID: 27940419
[TBL] [Abstract][Full Text] [Related]
12. Straightforward Access to a New Class of Dual DYRK1A/CLK1 Inhibitors Possessing a Simple Dihydroquinoline Core.
Ţînţaş ML; Peauger L; Alix F; Papamicaël C; Besson T; Sopková-de Oliveira Santos J; Gembus V; Levacher V
Molecules; 2022 Dec; 28(1):. PubMed ID: 36615235
[TBL] [Abstract][Full Text] [Related]
13. Exploration of the imidazo[1,2-b]pyridazine scaffold as a protein kinase inhibitor.
Bendjeddou LZ; Loaëc N; Villiers B; Prina E; Späth GF; Galons H; Meijer L; Oumata N
Eur J Med Chem; 2017 Jan; 125():696-709. PubMed ID: 27721154
[TBL] [Abstract][Full Text] [Related]
14. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
15. Imidazo[1,2-b]pyridazines as inhibitors of DYRK kinases.
Henderson SH; Sorrell FJ; Bennett JM; Fedorov O; Hanley MT; Godoi PH; Ruela de Sousa R; Robinson S; Navratilova IH; Elkins JM; Ward SE
Eur J Med Chem; 2024 Apr; 269():116292. PubMed ID: 38479168
[TBL] [Abstract][Full Text] [Related]
16. SGC-CLK-1: A chemical probe for the Cdc2-like kinases CLK1, CLK2, and CLK4.
Tiek D; Wells CI; Schröder M; Song X; Alamillo-Ferrer C; Goenka A; Iglesia R; Lu M; Hu B; Kwarcinski F; Sintha P; de Silva C; Hossain MA; Picado A; Zuercher W; Zutshi R; Knapp S; Riggins RB; Cheng SY; Drewry DH
Curr Res Chem Biol; 2023; 3():. PubMed ID: 38009092
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of a library of lead-like 2,4-bisheterocyclic substituted thiophenes as selective Dyrk/Clk inhibitors.
Schmitt C; Kail D; Mariano M; Empting M; Weber N; Paul T; Hartmann RW; Engel M
PLoS One; 2014; 9(3):e87851. PubMed ID: 24676346
[TBL] [Abstract][Full Text] [Related]
18. Identification of CLK1 Inhibitors by a Fragment-linking Based Virtual Screening.
Walter A; Chaikuad A; Loaëc N; Preu L; Knapp S; Meijer L; Kunick C; Koch O
Mol Inform; 2017 Apr; 36(4):. PubMed ID: 28000414
[TBL] [Abstract][Full Text] [Related]
19. Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease.
Jain P; Karthikeyan C; Moorthy NS; Waiker DK; Jain AK; Trivedi P
Curr Drug Targets; 2014 May; 15(5):539-50. PubMed ID: 24568585
[TBL] [Abstract][Full Text] [Related]
20. Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.
Kumar K; Man-Un Ung P; Wang P; Wang H; Li H; Andrews MK; Stewart AF; Schlessinger A; DeVita RJ
Eur J Med Chem; 2018 Sep; 157():1005-1016. PubMed ID: 30170319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
